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A B S T R A C T
Atherosclerosis, a chronic inﬂammatory disorder of the arteries, is responsible for most deaths in
westernized societies with numbers increasing at a marked rate in developing countries. The disease is
initiated by the activation of the endothelium by various risk factors leading to chemokine-mediated
recruitment of immune cells. The uptake of modiﬁed lipoproteins by macrophages along with defective
cholesterol efﬂux gives rise to foam cells associatedwith the fatty streak in the early phase of the disease.
As the disease progresses, complex ﬁbrotic plaques are produced as a result of lysis of foam cells,
migration and proliferation of vascular smoothmuscle cells and continued inﬂammatory response. Such
plaques are stabilized by the extracellular matrix produced by smooth muscle cells and destabilized by
matrix metalloproteinase from macrophages. Rupture of unstable plaques and subsequent thrombosis
leads to clinical complications such as myocardial infarction. Cytokines are involved in all stages of
atherosclerosis and have a profound inﬂuence on the pathogenesis of this disease. This review will
describe our current understanding of the roles of different cytokines in atherosclerosis together with
therapeutic approaches aimed at manipulating their actions.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Cardiovascular disease (CVD) is responsible for most mortality
worldwide and accounted for about 31.9% of all deaths in 2010 in
the United States alone [1]. The total direct and indirect costs from
CVD in 2010 were estimated at $315.4 billion [1]. Although
morbidity and mortality from CVD has decreased in the last two
decades, at least in the western world, it is expected that this
will reverse in the future because of a global increase in diabetes
and obesity along with an alarming rise in CVD in developing
countries in part due to acquisition of a westernized lifestyle.
Atherosclerosis, the underlying cause of myocardial infarction,
cerebrovascular accident or peripheral vascular disease, is the
major cause of deaths from CVD. Atherosclerosis is now recognized
as an inﬂammatory disorder of medium and large arteries initiated
by risk factors such as high plasma cholesterol levels and
hypertension [2]. Atherosclerosis develops during the lifespan of
an individual and involves a number of steps: activation of the
endothelium and recruitment of immune cells; monocyte differ-
entiation and foam cell formation; development of ﬁbrotic plaques
due to death of foam cells and migration and proliferation of
smooth muscle cells (SMCs); and plaque rupture and thrombosis
[2] (Fig. 1). Both the innate and adaptive immune response in
atherosclerosis is orchestrated by a range of cytokines, which
regulate all stages of the disease [2–4].
Cytokines are a diverse group of low-molecular weight proteins
with over 100 identiﬁed so far. Cytokines are clustered into several
classes such as the interleukins (IL), chemokines, colony-stimulat-
ing factors (CSF), tumor necrosis factors (TNF), the interferons (IFN)
and transforming growth factors (TGF) [2–4]. Many cytokines are
expressed in atherosclerotic plaques and all cells involved in the
disease are capable of producing cytokines and responding to them
[2]. They can be generally classiﬁed as pro- or anti-atherogenic[(Fig._1)TD$FIG]
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Fig. 1. Pathogenesis of atherosclerosis. The disease is initiated by the activation of th
subsequently gets modiﬁed (e.g. oxidized), together with other atherogenic factors. The a
proteins on their cell surface. This results in the recruitment and inﬁltration of immune
accompanied by increased expression of pattern recognition receptors on their surface
leading to the formation of lipid laden foam cells. Continued accumulation of modiﬁed L
foam cells resulting in lipid deposition (necrotic core) and ampliﬁcation of the inﬂamm
where they proliferate, uptake modiﬁed lipoproteins and secrete extracellular matrix
orchestrated by cytokines destabilizes such plaques via decreased production of ECM p
foam cells), increased production/activities of ECM degrading matrix metalloproteinase
rupture leads to platelet aggregation, coagulation and thrombus formation that ultimate
all the different stages in the pathogenesis of atherosclerosis (see text for details). Abb
metalloproteinase; SMC, Smooth muscle cells; TIMP, tissue inhibitor of metalloproteinthough the roles of some are not as clear-cut and often context-
dependent [2–4]. This reviewwill discuss the roles of key cytokines
in different stages of atherosclerosis. Although in vitro studies
using cell culture model systems have made a major contribution
in advancing our understanding of the roles of cytokines in the
cellular processes associated with atherosclerosis, the major focus
of this review will be on the outcome from studies using animal
model systems. In particular, two mouse models, the apolipopro-
tein (Apo) E-deﬁcient mice and the low-density lipoprotein
receptor (LDLr)-deﬁcient mice [5,6], have been particularly useful
in advancing our understanding of the molecular basis of
atherosclerosis and the roles of various cytokines in the disease
[2–4]. The use of bone marrow transplantation (BMT) approaches
in such models also informs on whether a particular phenotype is
driven by hematopoietic or non-hematopoietic cells [5,6]. These
mice can spontaneously form atherosclerotic lesions on a standard
chow diet but feeding of a high fat, western-type diet canmarkedly
speed up the development of the disease [5,6]. It should be noted
that caution needs to be exerted in the extrapolation of outcomes
from such mouse models to humans because of many differences
between the two species, including in lipoprotein metabolism
and the inﬂammatory response [7,8]. In addition, existing mouse
models are not particularly useful for investigating the steps
involved in the clinical complications of the disease, plaque
rupture [7]. It is therefore important that wherever possible key
ﬁndings are analyzed in the human context.
2. Initial stages of atherosclerosis: key roles for chemokines
Atherosclerotic plaques tend to form particularly at the inner
curvatures and branch points of arteries that are often associated
with disturbed blood ﬂow, and is augmented by other factors
such as high plasma low-density lipoprotein (LDL) concentration,• Destabilizaon of plaque by 
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forces associated with blood ﬂow have a profound effect on the
properties of endothelial cells (ECs) of the arteries [9]. Thus, shear
stress generally triggers an anti-atherogenic gene expression and
signal transduction proﬁle that is lost at sites of disturbed blood
ﬂow [9]. In addition, sites with disturbed blood ﬂow are associated
with changes in the morphology of ECs, increase in the
permeability to macromolecules such as LDL, and accumulation
of extracellular matrix (ECM) that causes the retention of such
particles [9]. Cytokines can modulate EC permeability [2,3]. For
instance, IFN-g and TNF-a cause reorganization of the actin and
tubulin cytoskeletons in ECs, thereby opening up gaps between
adjacent cells [10].
The activated ECs release a range of chemokines and other
cytokines that then cause the recruitment of circulating immune
cells, particularly monocytes and T lymphocytes [2]. In addition,
the ECs express adhesion proteins, such as intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1), that participate in the recruitment of immune cells
[2].
Chemokines are a large family of structurally related, chemoat-
tracting cytokines that are divided into subgroups on the basis of
the position of the amino terminal cysteine residues (CC, CXC,
CX3C, XC) [11–13]. Chemokines interact with receptors that
activate heterotrimeric G proteins and associated intracellular
signaling pathways [11,12]. The roles of chemokines in athero-
sclerosis, particularly in the recruitment of monocytes, has been
reviewed extensively [14–17] and hence is only brieﬂy addressed
here. Monocytes in the blood are generally classiﬁed inmice as the
most abundant classical Lys6Chigh [express high levels of CC-
chemokine receptor (CCR)-2, believed to be pro-inﬂammatory in
nature and their levels increase in hyperlipidemia) and less
frequent Ly6Clow [express CX3C-chemokine receptor 1 and per-
ceived to carry out a homeostatic function) [14,17]. The recruit-
ment of monocytes occurs in a number of stages: capture and
rolling; arrest; and extravasation [14–16]. The capture and rolling
phase for Lys6Chigh monocytes involves immobilization of CCL5
and CXCL1 on proteoglycans and P-selectins on ECs [14–16]. These
chemokines interact with receptors expressed on the surface of
invading monocytes [14–16]. The ﬁrm adhesion of monocytes to
ECs requires binding of adhesion molecules on ECs to integrins on
monocytes: VCAM-1 to integrina4b1 (very late antigen 4 or VLA4)
and ICAM-1 toaLb2 (lymphocyte function-associated antigen 1 or
LFA1) [14–16]. The transmigration of monocytes across the
endothelium is mediated by chemokines produced by not only
ECs but other cells present in the lesion such as SMCs and
emigrated leukocytes along with VCAM-1 and platelet endothelial
cell adhesion molecule-1 (PECAM-1) [14–16].
The roles of various chemokines and their receptors in
atherosclerosis have been analyzed in mouse model systems,
and the outcomes are summarized in Tables 1 and 2. It should be
noted that different studies have not always produced a consistent
outcome (e.g. CCR7) (Tables 1 and 2). In addition, there is often
a marked functional redundancy in the action of various
chemokines with further complexity produced by the ability of
some of them to interact with multiple receptors together with
individual receptors having many ligands [11–13]. In addition,
there are likely to be temporal expression pattern and function
of some chemokines during different stages of atherogenesis
[11–13]. Overall, the threemost prominent chemokine:chemokine
receptors involved in the transmigration of Ly6Chigh monocytes
include CCL2:CCR2, CX3CL1:CX3CR1, and CCL5-CCR5 [14,73].
Deﬁciency of these three-chemokine action leads to almost
complete attenuation of atherosclerosis in mouse model systems
[74]. The entry of patrolling Ly6Clow monocytes occurs less
frequently and tends to rely on the CX3CL1:CX3CR1 axis [14].Although chemokines were originally discovered in relation to
their roles in directing leukocytes to sites of inﬂammation, they
are now known to play a number of other important functions in
the disease [11–13]. For example, CX3CL1 can also serve as an
adhesion molecule [33]. CCL2 also impairs reverse cholesterol
transport (RCT) by repressing the expression of key proteins
implicated in the efﬂux of cholesterol from cells [75]. Manipulating
the chemokine:chemokine receptor axis represents a promising
therapeutic avenue [11–13]. Indeed, existing therapies such as
statins have been found to attenuate the expression of chemokine
and their receptors [76]. Other approaches that have shown
promise, at least in mouse model systems, are: manipulating
sialylation that affects the interaction of chemokines with their
cognate receptors [77]; antagonists/inhibitors of speciﬁc receptors
[49,65,71]; nano-particle-facilitated gene silencing [50]; broad
spectrum inhibitors such as viral proteins [78–80]; blocking
antibodies against chemokines or their receptors [11–13]; decoy
ligands that bind to the receptor but does not cause activation
(e.g. met-RANTES) [11–13]; and molecules that target chemokine
oligomerization [11–13]. Targeting multiple chemokines will be
necessary given the independent roles of some chemokines
[62,81]. It is also important to point out that not all chemokines
are pro-atherogenic. For example, CXCL5 limits macrophage foam
cell formation in mouse model systems [27].
Deﬁciency of many cytokines (e.g. IL-1RA, IL-10, IL-13, IL-18,
IL-19) is also associated with reduced macrophage recruitment
(see Tables 3 and 4 for a summary of the outcome of studies on
the roles interleukins and other cytokines respectively in mouse
model systems). Induced expression of chemokines and adhesion
molecules by ECs represents amajor mechanism for such an action
of these cytokines [2,3].
3. Foam cell and fatty streak formation: Key roles for cytokines
The normal function of monocyte recruitment in inﬂammation
is to participate in its resolution in order to ultimately decrease
further entry of immune cells, cause egress of existing cells
from inﬂammatory sites and efferocytosis of apoptotic cells
[2,14]. However, these homeostatic mechanisms are impaired in
atherosclerosis resulting in a continuous recruitment ofmonocytes
and reduced egress and efferocytosis of existing cells [2,14]. In
addition, local proliferation dominates macrophage accumulation
in atherosclerotic plaques [197].
In the arterial intima, monocytes can differentiate to macro-
phages or dendritic cells (DCs) depending on the cytokine signal
received with macrophage colony-stimulating factor (M-CSF) a
major facilitator of macrophage differentiation [2]. Recent studies
are highlighting the polarization and plasticity of macrophages
that is in part dictated by the cytokine signals [198–200]. A number
of macrophage phenotypes have been identiﬁed (e.g. M1, M2, M4)
with the twomajor ones being classically activatedM1 (thought to
be derived from Ly6Chigh-monocytes and produces pro-inﬂamma-
tory cytokines such as IL-6, IL-12 and TNF-a) and the alternatively
activated M2 (thought to be derived from Ly6Clow-monocytes and
produces anti-inﬂammatory cytokines such as IL-10 and TGF-b)
that aid in the resolution of inﬂammatory responses [2,198–200].
T-helper (Th)-1 cytokines such as IFN-g and IL-1b favor M1
differentiation whereas Th2 cytokines such as IL-4 and IL-13 are
required for M2 differentiation [198–200]. The pro-atherogenic
roles of IFN-g and IL-1b are well established (Tables 3 and 4) and
recent studies have shown that administration of IL-13 in the
LDLr/ model system drives M2 macrophage polarization and
inhibits atherosclerosis progression [121]. However, the role of
IL-4 in atherosclerosis is not clear-cut [101,102].
LDL tends to diffuse passively through EC junctions and its
retention is aided by interaction of its apoB moiety with
Table 1
The roles of key chemokines in atherosclerosis.
Chemokine Summary of studies using mouse model systems Ref.
CCL2 Hematopoietic overexpression in ApoE/model accelerates atherosclerosis without affecting lipoprotein proﬁle. Inhibition by
transfection of an N-terminal deletion mutant in skeletal muscle of ApoE/ mice limits progression and destabilization of
established plaques and normalizes levels of pro-inﬂammatory mediators. Deﬁciency reduces atherosclerosis in ApoE/ or
LDLr/ models. Local gene silencing using adenoviral vectors promotes plaque stabilization in the ApoE/.
[18–23]
CCL3 BMT in the LDLr/model system shows that deﬁciency of CCL3 reduces atherosclerotic burden and decreases accumulation of
neutrophils.
[24,25]
CCL5 Knockdown of Y-box binding protein-1, which controls CCL5 expression, reduces neointima formation following carotid
ligation in the ApoE/ model.
[26]
CXCL5 Inhibition in the ApoE/ model leads to macrophage foam cell accumulation in atherosclerotic plaques. The chemokine
modulates macrophage activation and stimulates cholesterol efﬂux together with associated changes in gene expression.
[27]
CXCL1 Blocking antibodies increases neointimal formation and inhibits endothelial recovery after carotid injury in ApoE/ model. [28]
CXCL10 Deﬁciency in the ApoE/model reduces atherosclerosis by modulating the local balance of effector and regulatory T cells with
increased levels of TGF-b and IL-10. Inhibition using neutralizing antibodies in the ApoE/ produces a stable plaque phenotype.
[29,30]
CXCL16 Deﬁciency in the LDLr/model exacerbates lesion formation. Overexpression promotes a vulnerable plaque phenotype in the
ApoE/ model.
[31,32]
CX3CL1 Deﬁciency in the ApoE
/ or LDLr/ models reduces atherosclerosis in the brachiocephalic artery but not in the aortic root. [33]
CCL17 Deﬁciency in the ApoE/ model reduces atherosclerosis that is dependent on Tregs. Expression of CCL17 by DCs limits
expansion of Tregs and enhances atherosclerosis. CCL17 blocking antibody expands Tregs and reduces atherosclerosis.
[34]
CCL19/CCL21 Transplantation of bone marrow from mice lacking both these chemokines in the LDLr/ model increases inﬂammatory
cellular inﬁltration but decreases expression of several pro-inﬂammatory cytokines. Plaque stability is increased but lesion
development remains unchanged.
[35]
CXCL12 Administration in the ApoE/ model promotes a more stable plaque phenotype and enhances the accumulation of smooth
muscle progenitor cells without promoting atherosclerosis.
[36]
CXCL4 Elimination from platelets reduces atherosclerosis in C57BL/6 and ApoE/ mice. [37]
MIF Deﬁciency in the LDLr/ model reduces atherosclerosis associated with impaired monocyte adhesion to the arterial wall.
Blockade inmicewith advanced atherosclerosis leads to plaque regression and reducesmonocyte and T-cell content in plaques.
Blockade in the LDLr/model following experimental angioplasty decreases vascular inﬂammation, cellular proliferation and
neointimal thickening. Inhibition in the ApoE/ model reduces aortic inﬂammation and, following vascular injury, shifts the
cellular composition of neointimal plaques to a stable phenotype with reduced inﬂammatory cells and increased SMC content.
[38–42]
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[2]. The accumulated LDL is subject to modiﬁcation such as
aggregation and oxidation. The latter to form oxidized LDL (OxLDL)
is in response to exposure to oxidants from the activatedTable 2
The roles of key chemokine receptors in atherosclerosis.
Receptor Summary of studies using mouse model systems
CCR1 Deﬁciency in the ApoE/model increases plaque area, T-cell conte
formation following wire injury.
CCR2 Deﬁciency in the ApoE/ model reduces lesion formation. Transp
model suppresses angiotensin II-mediated acceleration of atheros
Leiden model reduces overall atherosclerotic lesion development
Pharmacological inhibition reducesmacrophage inﬁltration in the A
RNA interference in the ApoE/ model reduces recruitment of Ly
infarct healing.
CCR5 Deﬁciency in the ApoE/ model protects against atherosclerosis
reduced inﬁltration of monocytes and decreased Th1 inﬂammatory
role in late-stage atherosclerosis was also identiﬁed involving mo
reduction in circulating levels of IL-6 and MCP-5. Antagonist atte
injury in mouse models. Transplantation of CCR5 deﬁcient bone m
increased IL-10 expression and reduced TNF-a levels.
CCR6 Deﬁciency in the LDLr/ model reduces atherosclerotic burden b
atherosclerosis also seen in the ApoE/ model accompanied by d
migration. BMT reveals importance of chemokine expressed by h
CCR7 Expression induced in an atherosclerosis regression model in Apo
ligands CCL19 and CCL21 preserved lesion size and foam cell conte
atherosclerosis by modulating T-cell entry and exit into lesions. In
disease by increasing T-cell accumulation. BMT conﬁrms the imp
CXCR2 Transplantation of CXCR2 deﬁcient bone marrow in the LDLr/ m
CXCR3 Blockade in the LDLr/ model using the antagonist NBI-74330 in
increasing Tregs. Deﬁciency in the ApoE/ model reduces early a
associated with upregulation of IL-10, IL-18BP, eNOS and Tregs.
CXCR4 Functional blockade in the ApoE/ or the LDLr/models promote
Antagonists reduce neointima formation without impairing endo
model. Deﬁciency of endothelial CXCR4 attenuates reendotheliali
vascular injury in ApoE/ mice.
CXCR6 Deﬁciency in the ApoE/ model decreases plaque formation and
CXCR7 Activation in the ApoE/ model improves hyperlipidemia by stim
CX3CR1 Deﬁciency in the ApoE/ model decreases atherosclerosis associ
Antagonist inhibits atherosclerosis in both ApoE/ and LDLr/ mendothelium and due to the action of enzymes such as 12/15-
lipooxygenase, myeloperoxidases and NADPH oxidases [2,201].
The effect of some cytokines on the oxidation of LDL bymonocytes/
macrophages or other cells involved in atherosclerosis along withRef.
nt and levels of IFN-g but doesn’t protect against neointima [43,44]
lantation of CCR2 deﬁcient bone marrow in the ApoE/
clerosis and abdominal aortic aneurysm, and in the ApoE3-
but has no effect on the progression of established plaques.
poE/model expressing human CCR2. Monocyte-targeted
-6Chigh monocytes, attenuates inﬂammation and improves
[22,45–50]
and is associated with a more stable plaque phenotype,
response, and increased production of IL-10. An important
dulation of macrophage accumulation in the plaque and
nuates atherosclerosis and reduces myocardial reperfusion
arrow in the LDLr/model attenuates atherosclerosis with
[43,51–54]
y affecting monocyte-mediated inﬂammation. Reduced
ecrease in both circulating levels of monocytes and their
ematopoietic cells.
[55,56]
E/ mice. Abrogation of function using antibodies against
nt in this model. Deﬁciency in the LDLr/model attenuates
contrast, deﬁciency in the ApoE/ model exacerbates the
ortance of CCR7 expressed by hematopoietic cells.
[57–59]
odel reduces macrophage content in established plaques. [60]
hibits atherosclerosis by reducing activated T-cells and
therosclerotic lesion development in the abdominal aorta
[61,62]
s atherosclerosis through deranged neutrophil homeostasis.
theliazation following carotid wire injury in the ApoE/
zation and stimulates neointima hyperplasia following
[63–66]
reduces T-cell and macrophage content. [67]
ulating cholesterol uptake in adipose tissue. [68]
ated with reduced recruitment of macrophages and DCs.
odels by modulating monocyte trafﬁcking.
[69–72]
Table 3
The roles of interleukins in atherosclerosis.
Interleukin Summary of studies using mouse model systems Ref.
IL-1a BMT in the LDLR/model demonstrated that macrophage-derived IL-1a but not IL-1b drives atherosclerosis. BMT in
the ApoE/ model also demonstrated the importance of IL-1a. Fatty acid-induced uncoupling of mitochondrial
respiration elicits inﬂammasome-independent IL-1a production that drives vascular inﬂammation in atherosclerosis.
Active immunization targeting IL-1a decreases both the inﬂammatory reaction and plaque progression in the ApoE/
model.
[82–84]
IL-1b Deﬁciency or blocking of the cytokine in the ApoE/ model decreases atherosclerosis and expression of several pro-
inﬂammatory genes. Deﬁciency of IL-1 receptor-1 in the ApoE/ model reduces atherosclerosis but was surprisingly
associatedwithmany unexpected features of plaque stability. BMT in thismodel showed that selective loss of IL-1 in the
vessel wall reduces plaque burden.
[85–91]
IL-1RA Overexpression in the LDLr/ model reduces foam-cell lesion size by affecting plasma cholesterol levels.
Overexpression in the ApoE/ model attenuates fatty streak formation. The IL-1/IL-1RA ratio plays a crucial role in
controlling vascular inﬂammation and atherosclerosis. Heterozygous deﬁciency in ApoE/ mice enhances early
atherosclerotic lesions with increased macrophage content and decreased level of SMCs. Deﬁciency in the C57BL/6J
background promotes neointimal formation after wire injury.
[92–97]
IL-2 Injection of the cytokine enhances atherosclerosis in the ApoE/ model whereas injection of anti-IL-2 antibodies
reduces this. Cytokine therapy with IL-2/anti-IL-2 monoclonal antibody in this model attenuates atherosclerosis by
expanding Tregs and modulating immune-inﬂammatory components.
[98,99]
IL-3 Transplantation of bone marrow from mice that are deﬁcient in the common b subunit of the IL-3/GM-CSF receptor in
the LDLr/ model reduces stem cell expansion and monocytosis along with macrophage and collagen content.
[100]
IL-4 Early study showed that deﬁciency in the ApoE/ model reduces atherosclerotic lesions. However, another in-depth
study involving exogenous delivery and/or genetic deﬁciency in ApoE/ or LDLr/models showed no involvement in
atherosclerotic lesion formation irrespective of the mode of disease induction.
[101,102]
IL-5 Transplantation of IL-15-deﬁcient bone marrow in the LDLr/model reduces levels of IgM that recognizes epitopes in
oxidized LDL and accelerates atherosclerosis.
[103]
IL-6 Injection of the cytokine in the ApoE/mice increases levels of pro-inﬂammatory cytokines and lesion size and use of
IL-6 lentivirus demonstrated the ability to destabilize plaques. Inhibition of IL-6 trans-signaling using the inhibitor,
soluble glycoprotein 130, reduces atherosclerosis by decreasing endothelial cell activation, inﬁltration of SMCs and
recruitment of monocytes. However, deﬁciency of the cytokine in both ApoE/ and LDLr/ models enhanced
atherosclerosis.
[104–109]
IL-10 BMT in the LDLr/ model showed deﬁciency of the cytokine accelerates atherosclerosis whereas its overexpression
inhibits advanced lesions, decreases cholesterol and phospholipid oxidation products in the aorta alongwithmonocytic
activation and produces a shift to Th2 phenotype. Deﬁciency in the ApoE/model increases atherosclerosis associated
with increased LDL levels, Th1 response, MMP and tissue factor activities, and markers of systemic coagulation and
vascular thrombosis. Deﬁciency in the ApoE*3-Leidenmice leads to increased neointima surface following cuff-induced
stenosis of the femoral artery. A marked inhibition of this along with reduction in plasma cholesterol levels and
expression of several pro-inﬂammatory cytokines was produced by overexpression of IL-10. The cytokine also
attenuates the response to wire carotid artery injury in wt mice. Gene therapy using IL-10 encoding viral vectors or
plasmids in ApoE/ or LDLr/ models reduces atherosclerosis associated with decreased inﬂammation, oxidative
stress, expression of pro-inﬂammatory markers and macrophage content of plaques.
[110–118]
IL-12 Blockade of function by vaccination in the LDLr/ model reduces atherosclerosis with increased SMC and collagen
content. Deﬁciency in the ApoE/model reduces lesion. Injection of the cytokine in the ApoE/model increases serum
levels of anti-oxidized LDL antibodies and accelerates atherosclerosis.
[101,119,120]
IL-13 Administration of cytokine in LDLr/ model promotes favorable plaque morphology by increasing lesional collagen
content, decreasing VCAM-dependent monocyte recruitment and inducing M2 macrophage phenotype. Deﬁciency of
the cytokine accelerates atherosclerosis.
[121]
IL-15 Neutralization of the cytokine in the LDLr/model using a DNA vaccination strategy reduces plaque size. Blockade of
the cytokine increases intimal thickening following carotid artery injury in C57BL/6.
[122,123]
IL-17 Studies on loss of SOCS3 expression in T-cells of LDLr/ model demonstrated protective role of the cytokine in
atherosclerosis. Transplantation of IL-17 receptor deﬁcient bone marrow in the LDLr/ model attenuates
atherosclerosis whereas deﬁciency of the cytokine in the ApoE/model has no effect on plaque burden but attenuates
vascular and systemic inﬂammation. In contrast, inhibition using neutralizing antibody in the ApoE/model prevents
atherosclerotic lesion progression by reducing inﬂammatory burden and cellular inﬁltration, and improving lesion
stability. Similarly, deﬁciency of the cytokine or its receptor in the ApoE/model reduces atherosclerosis and vascular
inﬂammation whereas injection of IL-17 promotes the disease. IL-17 exacerbates ferric chloride-induced arterial
thrombosis in rat carotid artery.
[124–134]
IL-18 Deﬁciency in the ApoE/model reduces atherosclerosis associated with decreased action of IFN-g, more stable plaque
phenotype and shift to Th2 immune response though a pro-atherogenic rolewas identiﬁed in one study. Administration
potentiates atherosclerosis associated with elevated levels of IFN-g and reduced plaque stability. Lack of endogenous
IFN-g ablated the effects of IL-18 on atherosclerosis. In vivo electrotransfer of an expression plasmid encoding IL-18
binding protein in the ApoE/ model attenuates atherosclerosis.
[135–140]
IL-19 Administration reduces atherosclerosis in the LDLr/ model by promotiong Th2 polarization, decreasing leukocyte
adhesion and suppressing pro-inﬂammatory gene expression. Also, reduces ligation-mediated neointimal hyperplasia
by decreasing activation of SMCs.
[141,142]
IL-20 Administration in the ApoE/ model promotes atherosclerosis. [143]
IL-25 Administration in the ApoE/ model reduces atherosclerosis via modulation of innate immune responses. [144]
IL-27 Deﬁciency of the cytokine or its receptor in the LDLr/model alongwith BMT and in vitro cell culture-based approaches
showed that IL-27 inhibits atherosclerosis by attenuating macrophage activation, uptake of modiﬁed LDL and pro-
inﬂammatory cytokine production. Transplantation of IL-27 receptor deﬁcient bone marrow in the LDL/ model
increases atherosclerotic development by skewing immune responses towards Th17 cells.
[145,146]
IL-33 Administration in the ApoE/model reduces atherosclerosis associated with decreased foam cell content and levels of
IFN-g, and increased levels of IL-4, -5 and -13. Cytokine produced a Th1 to Th2 shift and had higher levels of anti-OxLDL
antibodies. Mice treated with a soluble decoy receptor that neutralizes IL-33 developed larger plaques. Action of IL-33
was mediated in a IL-5-dependent manner.
[147,148]
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Table 4
The roles of other cytokines in atherosclerosis.
Cytokine Summary of studies using mouse model systems Ref.
GDF-15 Transplantation of GDF-15-deﬁcient bone marrow in LDLr/ model attenuates macrophage chemotaxis and
accumulation, and produces a stable plaque phenotype. Deﬁciency in the ApoE/ model inhibits atherosclerosis by
decreasing apoptotic cells and IL-6-dependent inﬂammatory response to vascular injury. Transgenic overexpression in
ApoE/ model reveals a protective role.
[149–152]
G-CSF Administration in the ApoE/model reduces atherosclerosis (2 studies) associated with decreased serum cholesterol,
increased circulating monocytes, and increased expression of IL-10 and Tregs. However, one study found increased
atherosclerosis by G-CSF.
[153–155]
GM-CSF Deﬁciency in the LDLr/ model showed that it promoted advanced plaque progression by increasing macrophage
apoptosis susceptibility. However, another study found reduced atherosclerosis associated with decreased content of
dendritic and T-cells and disruption of elastic ﬁbers adjacent to the lesion. Injection of viral-encoding GM-CSF in the
LDLr/ model increases atherosclerosis associated with oxidative stress, inﬂammation and adhesion protein
expression. Deﬁciency in the ApoE/ model increases lesion size associated with accumulation of macrophages and
reduction in collagen content. In contrast, administration in the ApoE/ model exacerbates atherosclerosis.
[114,156–158]
IFN-a Administration accelerates atherosclerosis in the LDLr/ model. [159]
IFN-b Administration promotes atherosclerosis in ApoE/ and LDLr/ models. In contrast, the cytokine attenuated
angiotensin II-accelerated atherosclerosis and vascular remodeling in ApoE/ model.
[160,161]
IFN-g Deﬁciency of receptor in ApoE/ model reduces atherosclerosis lesion size and lipid accumulation, and increases
collagen content. Deﬁciency of the cytokine attenuates atherosclerosis in ApoE/ or LDLr/ mice and BMT in this
model reveals the importance of cytokine expressed by the hematopoietic compartment. Administration in the ApoE/
model increases atherosclerosis associated with elevated levels of T-cells. Postnatal blocking of the function of the
cytokine in the ApoE/model via overexpression of soluble decoy receptor prevents atherosclerotic plaque formation
and stabilizes advanced plaques.
[162–168]
M-CSF Deﬁciency in the ApoE/ or LDLr/ models attenuates atherosclerosis. [169–172]
TGF-b Gene therapy in LDLr/ mice reduces atherosclerosis associated with decreased oxidative stress, inﬂammation and
adhesion protein expression. Inhibition of TGF-b signaling in the ApoE/model accelerates atherosclerosis associated
with increased inﬂammation and decreased collagen content. BMT reveals the importance of the cytokine expressed by
the hematopoietic compartment. Overexpression in the ApoE/mice reduces atherosclerosis by decreasing T-cell and
macrophage content and inﬂammatory cytokines, and increasing collagen levels. The protective effect of estradiol on
fatty streak formation in the ApoE/ model requires TGF-b. Disruption of TGF-b signaling in dendritic and T cells
affects atherosclerosis though one study found no effect in relation to T cells.
[173–182]
TNF-a Deﬁciency of the cytokine in the ApoE/ or APOE*3-Leiden models reduces atherosclerosis associated with decreased
foam cells and expression of several pro-inﬂammatory markers. BMT reveals important role of cytokine expressed by
the hematopoietic compartment. Transplantation of bone marrow deﬁcient in p55 TNF receptor in the LDLr/model
reduces atherosclerosis associated with decreased foam cells and expression of pro-inﬂammatory markers.
[93,183–191]
TNFSF12/TWEAK Genetic deﬁciency/inhibition in the ApoE/ model reduces atherosclerosis associated with diminished pro-
inﬂammatory response and enhanced plaque stability.
[192]
TRAIL Deﬁciency in the ApoE/ model accelerates atherosclerosis, vascular calciﬁcation, diabetes and plaque instability.
Systemic administration reduces atherosclerosis in this model.
[193–196]
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has been investigated though the outcome of these studies have
not often been consistent [202–206]. For example, TNF-a, IL-4 and
IL-13 promoted LDL oxidation [202–204] though contradictory
ﬁndings were obtained with IFN-g [205,206].
Macrophages express pattern recognition receptors (PRRs),
such as scavenger receptors (SRs), toll-like receptors (TLRs) and
nucleotide-binding oligomerization domain (NOD)-like receptors
(NLR), that participate in foam cell formation and/or elicit an
inﬂammatory response against foreign particles or endogenously
produced danger signals [2,14]. The SRs and to a certain extent
TLRs play critical roles in foam cell formation. For example,
minimally modiﬁed LDL (mmLDL) and its components stimulate
TLR4-dependent ﬂuid phase uptake of lipoproteins by macro-
phages [207]. SRs, such as SR-A1 and CD36, recognizemodiﬁed LDL
and uptake these particles to convert into lipid-laden foam cells
[2]. The uptake of LDL via the LDLr is under negative feedback
regulation through the sterol response element binding protein
(SREBP) regulatory pathway [2]. In contrast, the uptake ofmodiﬁed
LDL by SRs in not under such negative feedback regulation and
therefore causes uncontrolled uptake [2]. Mechanisms other than
SRs-mediated endocytosis, such as pinocytosis, phagocytosis and
macropinocytosis, also participate in the uptake of lipoproteins,
including native and modiﬁed LDL [2].
As shown in Tables 3 and 4, several cytokines modulate foam
cell formation in vivo; for example, IFN-g and TNF-a promote this
whereas IL-1RA and IL-33 are inhibitory. The formation of foam
cells involves dysfunction of a homeostatic mechanism thatcontrols the uptake, intracellular metabolism and efﬂux of
cholesterol by macrophages [2]. Several cytokines modulate
macrophage foam cell formation by disrupting such a homeostatic
mechanism via regulation of the expression and/or activity of key
genes implicated in these processes [2]. For example, IFN-g
promotes modiﬁed LDL uptake by inducing the expression of the
SR that binds phosphatidyl serine and oxidized lipoproteins (SR-
PSOX) [208] and our recent studies have shown that the
extracellular signal-regulated kinase (ERK)/signal transducer and
activator of transcription-1 (STAT1) signaling is required for the
macrophage uptake of modiﬁed LDL by this cytokine [209]. In
addition, the cytokine decreases cholesterol efﬂux by inhibiting the
expression of key proteins involved in this process, such as ATP-
binding cassette transporter (ABC)A1 and ApoE, and increasing
intracellular levels of chostereyl esters by augmenting the
expression/activity of acyl-CoA acyl transferase-1 (ACAT-1), which
is involved in the esteriﬁcation of cholesterol [2,210,211]. The TNF
superfamily members LIGHT (homologous to lymphotoxin,
exhibits inducible expression, and competes with HSV glycopro-
tein D for herpes virus entry mediator, a receptor expressed by T
lymphocytes), TWEAK and TNF-like protein 1A (TL1A) also
promote the uptake of modiﬁed LDL [2]. For instance, we have
shown that TL-1A stimulates macrophage foam cell formation by
increasing the uptake of modiﬁed LDL and intracellular cholesteryl
ester content and decreasing cholesterol efﬂux [212]. The cytokine
induced the expression of several SRs (SR-A, CD36, SR-PSOX) and
decreased the expression of ApoE, ABCA1 and ABCG1 [212]. In
contrast to these pro-inﬂammatory cytokines, TGF-b1, IL-10 and
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33 reduces foam cells in the ApoE/mice in vivo andmacrophages
in vitro by decreasing modiﬁed LDL uptake, reducing intracellular
content of cholesteryl esters and stimulating cholesterol efﬂux
[148]. These changes were associated with reduced expression of
key genes involved in the uptake and intracellular storage of
cholesteryl esters, such as SR-A1, CD36, SR-BI, adipocyte differenti-
ation related protein (ADRP) and ACAT-1, and increased expression
of those implicated in the intracellular trafﬁcking and efﬂux of
cholesterol [e.g. ApoE, ABCA1, ABCG1, (Niemann-Pick disease, type
C (NPC)-1, NPC-2] [148]. TGF-b acts in a similar manner [2,
213–215]. Additionally, TGF-b and IL-33 attenuate macropinocy-
tosis [216]. On the other hand, IL-10 inhibits foam cell formation by
enhancing both modiﬁed LDL uptake and cholesterol efﬂux [117].
4. Cytokines and the development of complex lesions
Cholesterol is toxic to cells and mechanisms exist to maintain
homeostasis. For example, derivatives of cholesterol, such as
oxysterols, activate liver X receptors (LXRs) that then stimulate
cholesterol efﬂux by inducing the expression of ABCA1 and
ABCG1 [217]. LXRs also attenuate gene expression associated with
inﬂammation via transrepression [217]. Cytokines, on the other
hand, attenuate the actions of LXRs. For instance, IFN-g inhibits
LXR signaling [218] and the expression of LXR-a is decreased
during the hepatic acute phase response [219]. Continued inﬂam-
mation ultimately causes the cholesterol homeostatic mechanisms
to become overwhelmed during atherosclerosis. This leads to
endoplasmic reticulum (ER) stress in macrophages and, together
with other insults, results in cell death by apoptosis and necrosis
[2,14]. Defective clearance of such apoptotic cells (efferocytosis)
continues to result in lipid accumulation in the atherosclerotic
lesions [2,14]. Efferocytosis and components involved in the process
are also subject to regulation by cytokines [220,221].
Defective lipid homeostasis is instrumental in the ampliﬁcation
of the inﬂammatory response and activation of the immune
response [14]. Thus, a number of ‘‘danger signals’’ are produced
from modiﬁcation of LDL and lysis of foam cells that activate PRR,
such as SRs, TLRs and NLRs, expressed by macrophages [14]. For
example, the uptake of cholesterol crystals, which have been
observed in early lesions, by macrophages via macropinocytosis
activates the NLR family, pyrin domain containing 3 (NLRP3)
inﬂammasome [222]. The process involves lysosomal destabiliza-
tion and release of reactive oxygen species (ROS) and proteases
that then activate NLRP3 inﬂammasome leading to processing and
secretion of IL-1b and IL-18, and subsequent ampliﬁcation of the
inﬂammatory response [222]. In addition, increases in intracellular
cholesterol by other mechanisms (e.g. SRs-mediated uptake) leads
to the formation of intracellular cholesterol crystals and activation
of NLRP3 inﬂammasome [223]. Furthermore, mmLDL, which is
not recognized by SRs, causes production of pro-inﬂammatory
cytokines via a TLR4-dependent manner [224]. Moreover, OxLDL
uptake by CD36 causes expression of cytokines via a mechanism
involving TLR2-TLR4 [225].
Antigen presenting cells, such as macrophages and DCs, are
essential for the adaptive immune responses as they engulf and
process antigens, and present them on the cell surface in
association major histocompatibility complexes (MHC) for recog-
nition by T-cells [226,227]. A range of T-cells exists and many
studies have investigated their roles in atherosclerosis [226,227].
In general, Th1 cells are most abundant in atherosclerotic plaques,
secrete cytokines such as IFN-g, TNF-a and IL-2 and are pro-
atherogenic, whereas Tregs, which produce TGF-b and IL-10, are
anti-atherogenic [226,227]. In contrast, the roles of Th2 cells
(secrete IL-4, IL-5 and IL-13) and Th17 cells (produce IL-17A/F
alongwith IL-22 and IL-23) are not clear-cut [226,227]. The actionsof some cytokines on atherosclerosis (e.g. IL-10, IL-18, IL-19, IL-33,
TGF-b) are mediated, at least in part, by modulating T-cell
activation/levels/actions (Tables 3 and 4). Th1 commitment is
mainly triggered by IFN-g and IL-12, IL-6 and IL-13 play an
important role in Th2 differentiation, TGF-b and IL-6 are necessary
for Th17 differentiation, and generation of Tregs depends on TGF-b
[227]. In addition to T-cells, other immune cells, such as DCs,
natural killer (NK) cells, NKT cells, subsets of B cells, mast cells and
neutrophils play an important role in atherosclerosis and
contribute to the inﬂammatory responses in this disease [226,227].
SMCs also play an important role in atherosclerosis and more
advanced lesionsaregenerallycoveredwithaﬁbrouscap, composed
of SMCs and ECM components produced by them, and lipid-rich
necrotic core [2]. Migration of SMCs from the media to the intima
alongwith their proliferation is controlled by various growth factors
produced by macrophages, ECs and T-cells [228,229]. SMCs also
express SRs on their cell surface and can uptake modiﬁed LDL to
form foam cells [228,229]. Cytokines can modulate the process
by regulating the expression of SRs in isolation or synergistically
with growth factors [228,229]. In addition, IL-1b disrupts the
cholesterol-mediated LDLr feedback regulation in these cells and
produces increased expression of this receptor [230].
5. Roles of cytokines in plaque stability and rupture
The continued inﬂammatory response ultimately leads to the
destabilization of atherosclerotic plaques via the action of pro-
inﬂammatory cytokines. Indeed, studies in mouse model systems
have shown that IFN-g, IL-18, GDF-15 and TWEAK destabilize
plaques whereas TGF-b causes stabilization (Tables 3 and 4).
Cytokines modulate a number of steps in the control of plaque
stability and rupture. For instance, some, such as IFN-g, TNF-a and
IL-1b, promote apoptosis of macrophages along with foam cells
leading to enlargement of the lipid core [231]. In addition, such
cytokines stimulate apoptosis of SMCs leading to thinning of the
ﬁbrous cap [228,232,233]. Pro-inﬂammatory cytokines also inhibit
the synthesis of plaque stabilizing components of the ECM
produced by SMCs [232,233]. For example, IFN-g inhibits the
synthesis of collagen by SMCs [234]. Further remodeling of the
ECM is controlled by a range of proteases, particularly matrix
metalloproteinases (MMPs), and their inhibitors (tissue inhibitor
of metalloproteinases—TIMPs) produced by macrophages and
other vascular cells [235,236]. The expression and/or activities of
MMPs and TIMPs are regulated by cytokines [235,236]. Vulnerable
plaques have very few SMCs and high macrophage content, and
are susceptible to rupture leading to thrombosis [2,232,233]. Key
components involved in thrombosis are also subject to regulation
by cytokines. For example, studies in mouse model systems have
shown that deﬁciency of IL-10 is associated with tissue factor (TF)
activities together with markers of systemic coagulation and
vascular thrombosis [111]. In addition, the interaction of TWEAK
with its receptor, ﬁbroblast growth factor-inducible 14 (Fn14),
stimulates the expression of plasminogen activator inhibitor (PAI)-
1 and TF by SMCs [237]. Furthermore, the production of TF is
activated by a number of cytokines such as TNF-a, IL-1, IL-6, IL-8
and IFN-g [238]. Similarly, the expression of PAI-1 is modulated in
inﬂammatory conditions [239,240]. Pro-inﬂammatory cytokines
also suppress natural anticoagulant mechanisms, such as the
protein C pathway [241].
6. Conclusions and therapeutic perspectives
Inﬂammation plays a pivotal role in all stages of atherosclero-
sis: endothelial dysfunction; recruitment of immune cells;
modiﬁcation of LDL; foam cell formation; apoptosis of foam cells;
plaque rupture; and thrombosis. The inﬂammatory response in
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immune system via the action of cytokines. Our understanding of
the roles of such cytokines has recently advanced considerably
mainly via studies using mouse model systems (summarized in
Tables 1–4). Attenuating cytokine-induced inﬂammation and
promoting the actions of anti-inﬂammatory cytokines represent
potential therapeutic avenues. Indeed, statins and athero-protective
agonists of nuclear receptors attenuate signaling and gene expres-
sionmediated by certain cytokines [217,242,243], and this could be
responsible, at least, in part for their beneﬁcial effects. In addition,
the athero-protective effects of certain agents (e.g. estradiol) on
atherosclerosis in mouse model systems have been attributed to
TGF-b [177].
A number of anti-inﬂammatory therapies aimed at manipulat-
ing cytokine actions are currently being evaluated [2,11,243]. For
example, the Cardiovascular Inﬂammation Reduction Trial (CIRT)
has been initiated to evaluate the efﬁcacy of low doses of
methotrexate, which has proved beneﬁcial in the treatment of
the inﬂammatory disorders rheumatoid arthritis and psoriasis, for
the secondary prevention of myocardial infarction [244]. In
addition, a phase II clinical trial of canakinumab, IL-1b neutralizing
antibody, reported lowering of inﬂammatory markers and formed
the basis of a larger phase III, secondary prevention Canakinumab
Anti-inﬂammatory Thrombosis Outcomes Study (CANTOS) [243,
245,246]. A monoclonal antibody (MLN1202) that targets interac-
tion of CCL2 with its receptor has also been evaluated on a smaller
scale with reduction in the levels of the acute phase reactant
C-reactive protein [247].
Therapeutic approaches need not be restricted to cytokines
themselves. For instance, many studies in mouse model systems
have demonstrated the protective roles of Tregs and cytokines
produced by them (IL-10 and TGF-b) [226,227]. Many studies are
investigating the potential of approaches that augment the levels/
actionof Tregs or stimulate immune tolerance to antigens associated
with atherosclerosis [226,227]. Manipulating cytokine signaling
represents another approach and could include small molecule
inhibitors thatattenuate theactionofpro-inﬂammatorycomponents
or enhance those that are present naturally to dampen inﬂammation
(e.g. suppressors of cytokine signaling—SOCS) [2,3,11]. Noncoding
RNA, particularly microRNA (miRNA), are emerging as future
potential targets in dampening cytokine-mediated inﬂammation
in atherosclerosis [248]. For example, deﬁciency of mIR155, whose
expression is stimulated bymiR-342-5p [249], reduces inﬂammato-
ry responses in mouse model systems [250]. Pro-inﬂammatory
cytokines induces miR-146a/b in ECs, which then acts as a negative
feedback loop to control pro-inﬂammatory signaling in EC activation
[251]. Future research will inform on the potential of miRNA
therapeutics and reﬁne current approaches aimed at manipulating
cytokine actions in atherosclerosis.
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